CNO's tiny size of $22M makes it difficult to attract investors in an uncertain market. Shares are down 42% YTD. It has little cash and but revenue is growing (from a very low base). It has broken even in some years and cash flow, while barely positive, is at least not negative. Insiders own 16%, Omni Lite (OML) owns 15%. Nanotech may be the next big thing but we are certainly not there yet. CNO has had recent good news with purchase orders. Typically, we would never suggest such a small company. But if it is held, we would be OK keeping it. The decline this year seems a bit much based on its fundamentals and potential. EAGR is a bit larger at $29M, down 40% YTD. It has $7.6M cash. Revenue is quite high at $92M expected this year, but this is lower than in 2022. It is cash flow positive and should make 5 cents per share this year (one analyst). It is buying back stock, though it did miss estimates in its last quarter. The market backdrop is not great for microcaps, but this of course could change. For very very speculative investors we would see this as a HOLD, considering its potential, revenue base, and current cash. Note that these comments assume an investor has held these for a while already, and is prepared for the possibility of these dropping a lot more if things do not improve. They are not BUY suggestions if they are not owned.
5i Research Answer: